PMID- 36460660
OWN - NLM
STAT- MEDLINE
DCOM- 20221206
LR  - 20230109
IS  - 2059-3635 (Electronic)
IS  - 2095-9907 (Print)
IS  - 2059-3635 (Linking)
VI  - 7
IP  - 1
DP  - 2022 Dec 2
TI  - Recent advances in developing active targeting and multi-functional drug delivery 
      systems via bioorthogonal chemistry.
PG  - 386
LID - 10.1038/s41392-022-01250-1 [doi]
LID - 386
AB  - Bioorthogonal chemistry reactions occur in physiological conditions without 
      interfering with normal physiological processes. Through metabolic engineering, 
      bioorthogonal groups can be tagged onto cell membranes, which selectively attach 
      to cargos with paired groups via bioorthogonal reactions. Due to its simplicity, 
      high efficiency, and specificity, bioorthogonal chemistry has demonstrated great 
      application potential in drug delivery. On the one hand, bioorthogonal reactions 
      improve therapeutic agent delivery to target sites, overcoming off-target 
      distribution. On the other hand, nanoparticles and biomolecules can be linked to 
      cell membranes by bioorthogonal reactions, providing approaches to developing 
      multi-functional drug delivery systems (DDSs). In this review, we first describe 
      the principle of labeling cells or pathogenic microorganisms with bioorthogonal 
      groups. We then highlight recent breakthroughs in developing active targeting 
      DDSs to tumors, immune systems, or bacteria by bioorthogonal chemistry, as well 
      as applications of bioorthogonal chemistry in developing functional bio-inspired 
      DDSs (biomimetic DDSs, cell-based DDSs, bacteria-based and phage-based DDSs) and 
      hydrogels. Finally, we discuss the difficulties and prospective direction of 
      bioorthogonal chemistry in drug delivery. We expect this review will help us 
      understand the latest advances in the development of active targeting and 
      multi-functional DDSs using bioorthogonal chemistry and inspire innovative 
      applications of bioorthogonal chemistry in developing smart DDSs for disease 
      treatment.
CI  - (c) 2022. The Author(s).
FAU - Yi, Wenzhe
AU  - Yi W
AD  - State Key Laboratory of Drug Research & Center of Pharmaceutics, Shanghai 
      Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, 201203, 
      China.
FAU - Xiao, Ping
AU  - Xiao P
AD  - State Key Laboratory of Drug Research & Center of Pharmaceutics, Shanghai 
      Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, 201203, 
      China.
FAU - Liu, Xiaochen
AU  - Liu X
AD  - State Key Laboratory of Drug Research & Center of Pharmaceutics, Shanghai 
      Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, 201203, 
      China.
FAU - Zhao, Zitong
AU  - Zhao Z
AD  - State Key Laboratory of Drug Research & Center of Pharmaceutics, Shanghai 
      Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, 201203, 
      China.
FAU - Sun, Xiangshi
AU  - Sun X
AD  - State Key Laboratory of Drug Research & Center of Pharmaceutics, Shanghai 
      Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, 201203, 
      China.
FAU - Wang, Jue
AU  - Wang J
AD  - State Key Laboratory of Drug Research & Center of Pharmaceutics, Shanghai 
      Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, 201203, 
      China.
FAU - Zhou, Lei
AU  - Zhou L
AD  - State Key Laboratory of Drug Research & Center of Pharmaceutics, Shanghai 
      Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, 201203, 
      China.
FAU - Wang, Guanru
AU  - Wang G
AD  - State Key Laboratory of Drug Research & Center of Pharmaceutics, Shanghai 
      Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, 201203, 
      China.
FAU - Cao, Haiqiang
AU  - Cao H
AD  - State Key Laboratory of Drug Research & Center of Pharmaceutics, Shanghai 
      Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, 201203, 
      China.
FAU - Wang, Dangge
AU  - Wang D
AD  - State Key Laboratory of Drug Research & Center of Pharmaceutics, Shanghai 
      Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, 201203, 
      China. dgwang@simm.ac.cn.
AD  - Yantai Key Laboratory of Nanomedicine & Advanced Preparations, Yantai Institute 
      of Materia Medica, Yantai, 264000, China. dgwang@simm.ac.cn.
FAU - Li, Yaping
AU  - Li Y
AUID- ORCID: 0000-0002-0574-6966
AD  - State Key Laboratory of Drug Research & Center of Pharmaceutics, Shanghai 
      Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, 201203, 
      China. ypli@simm.ac.cn.
AD  - Shandong Laboratory of Yantai Drug Discovery, Bohai Rim Advanced Research 
      Institute for Drug Discovery, Yantai, 264000, China. ypli@simm.ac.cn.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20221202
PL  - England
TA  - Signal Transduct Target Ther
JT  - Signal transduction and targeted therapy
JID - 101676423
SB  - IM
MH  - Prospective Studies
MH  - Drug Delivery Systems
MH  - *Nanoparticles
MH  - Cell Membrane
MH  - *Bacteriophages
PMC - PMC9716178
COIS- The authors declare no competing interests.
EDAT- 2022/12/03 06:00
MHDA- 2022/12/07 06:00
PMCR- 2022/12/02
CRDT- 2022/12/02 23:16
PHST- 2022/08/03 00:00 [received]
PHST- 2022/11/07 00:00 [accepted]
PHST- 2022/10/25 00:00 [revised]
PHST- 2022/12/02 23:16 [entrez]
PHST- 2022/12/03 06:00 [pubmed]
PHST- 2022/12/07 06:00 [medline]
PHST- 2022/12/02 00:00 [pmc-release]
AID - 10.1038/s41392-022-01250-1 [pii]
AID - 1250 [pii]
AID - 10.1038/s41392-022-01250-1 [doi]
PST - epublish
SO  - Signal Transduct Target Ther. 2022 Dec 2;7(1):386. doi: 
      10.1038/s41392-022-01250-1.